Read the record
Read the records behind the answers.
Start with the record that matches your question. The short notes below explain what each source helps you check.
Semax: status and limits
FDA's July 2026 report for its advisory meeting reviews human studies and product quality. Staff recommended keeping Semax off the special ingredient list.
The page marked current to April 22, 2026 lists the request to allow Semax in compounding as withdrawn. FDA's safety concerns are still printed there.
This is the meeting page; as checked on September 30, 2026, it held no official vote record for the Semax discussion.
FDA explains how medicines are made to order and what it does not check before those medicines reach patients.
Human research: read the results
These links open abstracts, meaning short summaries of the papers. They do not give every detail of the full studies.
The small healthy-adult study reports changes on a brain scan; it does not establish better focus in everyday life.
This short summary reports improved recovery. It does not say whether groups were chosen by chance or whether patients and researchers knew who received Semax.
Check a doctor's or pharmacy's record
The Federation of State Medical Boards provides this directory with links to websites belonging to the state and territorial medical boards.
FDA's page leads to state pharmacy licence searches. Check the exact name supplied by the service.
The group suggests rules for state medical boards to use. These suggestions are not a law for the whole country; each state's own rules decide what is required.
This number names a drug in FDA's records. FDA says the number does not mean the drug is approved.
Report a product problem
Patients can use MedWatch to report an unwanted experience with a medical product.
The National Library of Medicine page explains severe allergic symptoms and when to seek emergency care.